Abeona Therapeutics Inc.

NasdaqCM:ABEO Stock Report

Market Cap: US$261.7m

Abeona Therapeutics Management

Management criteria checks 2/4

Abeona Therapeutics' CEO is Vish Seshadri, appointed in Oct 2021, has a tenure of 3.25 years. total yearly compensation is $2.85M, comprised of 19.5% salary and 80.5% bonuses, including company stock and options. directly owns 2.08% of the company’s shares, worth $5.44M. The average tenure of the management team and the board of directors is 3.3 years and 3.8 years respectively.

Key information

Vish Seshadri

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage19.5%
CEO tenure3.3yrs
CEO ownership2.1%
Management average tenure3.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Sep 23
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

May 01
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Jan 04
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16
Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31
Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28
Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21
Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19
How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15
What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

CEO Compensation Analysis

How has Vish Seshadri's remuneration changed compared to Abeona Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$3mUS$555k

-US$54m

Sep 30 2023n/an/a

-US$45m

Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$505k

-US$43m

Sep 30 2022n/an/a

-US$83m

Jun 30 2022n/an/a

-US$84m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$2mUS$255k

-US$85m

Compensation vs Market: Vish's total compensation ($USD2.85M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Vish's compensation has increased whilst the company is unprofitable.

CEO

Vish Seshadri (48 yo)

3.3yrs

Tenure

US$2,847,442

Compensation

Dr. Vishwas Seshadri, also known as Vish, Ph.D. & M.B.A., serves as Chief Executive Officer, President and Director at Abeona Therapeutics Inc. since October 15, 2021. He served as the Senior Vice Presiden...

Leadership Team

NamePositionTenureCompensationOwnership
Vishwas Seshadri
President3.3yrsUS$2.85m2.08%
$ 5.4m
Joseph Vazzano
Chief Financial Officer2.8yrsUS$1.49m0.84%
$ 2.2m
Brendan O'Malley
Senior VP & General Counsel4.8yrsUS$1.17m0.63%
$ 1.6m
Brian Kevany
Senior VP3.6yrsno datano data
Gregory Gin
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Alison Hardgrove
Chief People Officer3yrsno datano data
Jon Voss
VP & Head of Quality3.3yrsno datano data
Madhav Vasanthavada
Senior VP1.3yrsno datano data
Carl Denny
Senior Vice President of Regulatory Affairsno datano datano data

3.3yrs

Average Tenure

51.5yo

Average Age

Experienced Management: ABEO's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vishwas Seshadri
President3.3yrsUS$2.85m2.08%
$ 5.4m
Mark Alvino
Independent Director3.8yrsUS$336.14k0.17%
$ 435.5k
Faith Charles
Independent Director3.8yrsUS$336.14k0.26%
$ 684.6k
Donald Wuchterl
Independent Director3.8yrsUS$330.52k0.26%
$ 689.4k
Eric Crombez
Independent Directorless than a yearno data0.025%
$ 66.5k
Christine Berni-Silverstein
Independent Director4.8yrsUS$324.89k0.22%
$ 586.8k
Leila Alland
Independent Director3.8yrsUS$336.14k0.27%
$ 711.9k
Steven Gray
Member of Scientific Advisory Board7.8yrsno datano data
Erika Augustine
Member of Scientific Advisory Board7.8yrsno datano data
Jonathon Mink
Member of Scientific Advisory Board7.8yrsno datano data
John Cooper
Member of Scientific Advisory Board7.8yrsno datano data
Michael Amoroso
Chairman of the Board3.8yrsUS$351.14k0.33%
$ 869.1k

3.8yrs

Average Tenure

51yo

Average Age

Experienced Board: ABEO's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 01:00
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abeona Therapeutics Inc. is covered by 22 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
George ZavoicoB. Riley Securities, Inc.
Elemer PirosCantor Fitzgerald & Co.